je.st
news
Tag: epoch
Forty Under 40: Garin Wente, Epoch Resources LLC
2020-12-29 11:35:00| OGI
Todays featured Forty Under 40 honoree is Garin Wente, CEO and co-founder of Epoch Resources LLC, an independent oil and gas company focused on the Anadarko and Appalachian basins.
Tags: resources
llc
forty
epoch
Baltimore Spirits Co's Post Epoch Rye - Product Launch
2020-03-19 11:55:00| Daily beverage news and comment - from just-drinks.com
Baltimore Spirits Co has released the first speciality whiskey of the year from its 'Post Epoch' range - a series of one-off extensions of flagship brand Epoch Rye.
Tags: post
product
launch
baltimore
Proposed Anthropocene epoch rustles jimmies of dissenting geologists
2016-08-31 19:31:52| Extremetech
Scientists say we've left an indelible mark on the history of our planet. But is it a deep enough footprint to mark the beginning of a new epoch?
Tags: proposed
epoch
geologists
anthropocene
What Eocene epoch tells us about global warming now
2016-04-26 10:21:00| Climate Ark Climate Change & Global Warming Newsfeed
Christian Science Monitor: By delving into the mysteries of Earth's climate 50 million years ago, scientists hope to understand how our planet may cope with global warming, providing independent insight into today's climate models. Ancient climates can help us understand the dynamics of future climate change, the impacts of global warming, and the accuracy of current climate models, say scientists. In a recent study, published Monday in the journal Nature, researchers delved into the character of Earth's climate during...
Tags: now
global
warming
tells
Merck Completes Enrollment in Pivotal Phase 3 EPOCH Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimers Disease
2016-01-28 14:00:26| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. APECS Study Investigating Verubecestat in Patients with Prodromal Alzheimers Ongoing KENILWORTH, N.J. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today confirmed the completion of enrollment for the EPOCH trial, a Phase 2/3 randomized, placebo-controlled, parallel-group, double-blind study of verubecestat, formerly known as MK-8931, the companys investigational oral small molecule selective beta secretase (BACE1) inhibitor, in patients with mild-to-moderate Alzheimers disease (AD). The ongoing study commenced in November 2012, completed enrollment in the fourth quarter of 2015 and is estimated to reach primary trial completion in July 2017. Language: English read more